In a filing, Amphastar Pharmaceuticals Inc revealed its Director Petersen Floyd F. unloaded Company’s shares for reported $20837.0 on May 01 ’24. In the deal valued at $41.67 per share,500 shares were sold. As a result of this transaction, Petersen Floyd F. now holds 78,833 shares worth roughly $3.37 million.
Then, Petersen Floyd F. sold 500 shares, generating $21,714 in total proceeds. Upon selling the shares at $43.43, the Director now owns 79,333 shares.
Before that, PETERS WILLIAM J sold 18,136 shares. Amphastar Pharmaceuticals Inc shares valued at $842,883 were divested by the CFO, EVP & TREASURER at a price of $46.48 per share. As a result of the transaction, PETERS WILLIAM J now holds 111,490 shares, worth roughly $4.77 million.
JP Morgan initiated its Amphastar Pharmaceuticals Inc [AMPH] rating to an Overweight in a research note published on March 05, 2024; the price target was $60. A number of analysts have revised their coverage, including BofA Securities’s analysts, who began to cover the stock in mid November with a ‘”a Neutral”‘ rating.
Price Performance Review of AMPH
On Tuesday, Amphastar Pharmaceuticals Inc [NASDAQ:AMPH] saw its stock jump 0.21% to $42.77. Over the last five days, the stock has gained 3.68%. Amphastar Pharmaceuticals Inc shares have fallen nearly -30.85% since the year began. Nevertheless, the stocks have risen 17.21% over the past one year. While a 52-week high of $67.66 was reached on 01/05/24, a 52-week low of $36.06 was recorded on 04/18/24. SMA at 50 days reached $43.21, while 200 days put it at $50.99. A total of 0.25 million shares were traded, compared to the trading of 0.21 million shares in the previous session.
Levels Of Support And Resistance For AMPH Stock
The 24-hour chart illustrates a support level at 41.98, which if violated will result in even more drops to 41.20. On the upside, there is a resistance level at 43.51. A further resistance level may holdings at 44.26. The Relative Strength Index (RSI) on the 14-day chart is 54.57, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.31, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 13.89%. Stochastics %K at 84.88% indicates the stock is a selling.
The most recent change occurred on July 29, 2022 when CapitalOne began covering the stock and recommended ‘”an Overweight”‘ rating along with a $44 price target.
